Atlas Trials

A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients

Clinical trial NCT03013504 · COMPLETED

Trial details

NCT number
NCT03013504
Sponsor
Prestige Biopharma Limited
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
HER2 Positive Breast Cancer
Start date
2018-02-19
Primary completion
2019-04-19
Enrollment
503

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.